Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023

MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  225.21
+4.52 (2.05%)
AAPL  275.70
+4.21 (1.55%)
AMD  215.43
+11.65 (5.72%)
BAC  52.03
+0.47 (0.92%)
GOOG  317.34
+17.69 (5.90%)
META  614.16
+19.91 (3.35%)
MSFT  475.61
+3.49 (0.74%)
NVDA  182.69
+3.81 (2.13%)
ORCL  200.87
+2.11 (1.06%)
TSLA  419.37
+28.28 (7.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.